Camoutsis Charalambos, Trafalis Dimitrios, Pairas George, Papageorgiou Athanasios
Laboratory of Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece.
Farmaco. 2005 Oct;60(10):826-9. doi: 10.1016/j.farmac.2005.07.006. Epub 2005 Aug 31.
The p-[N,N-bis(2-chloroethyl)amino]phenylacetic acid esters of hecogenin and aza-homo-hecogenin have been prepared and their antineoplastic activity was evaluated against two basic drug screening systems in rodents, P388 lymphocytic and L1210 lymphoid murine leukemias. Among the compounds tested, the p-[N,N-bis(2-chloroethyl)amino]phenylacetic acid ester of aza-homo-hecogenin was appeared to possess a significant higher antileukemic effect. These results support that the alkylating esters of hecogenin produce important antitumor activity as well as, indicate that the aza-homo-hecogenin ester exhibits significantly higher activity due to lactam group (-NHCO-) modification.
海柯皂苷元及氮杂高海柯皂苷元的对-[N,N-双(2-氯乙基)氨基]苯乙酸酯已被制备出来,并针对啮齿动物的两种基本药物筛选系统——P388淋巴细胞性白血病和L1210淋巴样小鼠白血病,对它们的抗肿瘤活性进行了评估。在所测试的化合物中,氮杂高海柯皂苷元的对-[N,N-双(2-氯乙基)氨基]苯乙酸酯似乎具有显著更高的抗白血病效果。这些结果支持海柯皂苷元的烷基化酯产生重要的抗肿瘤活性,同时表明氮杂高海柯皂苷元酯由于内酰胺基团(-NHCO-)修饰而表现出显著更高的活性。